Skip to main content
Erschienen in: Diabetologia 10/2003

01.10.2003 | Article

Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients

verfasst von: M. Saraheimo, A.-M. Teppo, C. Forsblom, J. Fagerudd, P.-H. Groop, MD, on behalf of the FinnDiane Study Group

Erschienen in: Diabetologia | Ausgabe 10/2003

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Increased concentrations of C-reactive protein and interleukin-6, a finding suggestive of the presence of inflammation, have been observed in Type 2 diabetes. In such patients, C-reactive protein was predictive of diabetic nephropathy. Studies on low-grade inflammatory markers and nephropathy in Type 1 diabetic patients have shown conflicting results. Therefore we studied whether low-grade inflammation is associated with diabetic nephropathy in Type 1 diabetic patients.

Methods

We divided 194 Type 1 diabetic patients into three groups from the Finnish Diabetic Nephropathy Study based upon their albumin excretion rate. Patients with normoalbuminuria (n=67) had no antihypertensive medication or signs of cardiovascular disease, while patients with microalbuminuria (n=64) or macroalbuminuria (n=63) were all treated with an angiotensin-converting enzyme inhibitor, a drug that could attenuate low-grade inflammation. As a measure of insulin sensitivity we used estimated glucose disposal rate. C-reactive protein was measured by radioimmunoassay and interleukin-6 by high sensitivity enzyme immunoassay.

Results

C-reactive protein was higher in micro- and macroalbuminuric patients compared to normoalbuminuric patients (normoalbuminuria 2.0±1.7, microalbuminuria 2.6±1.7, macroalbuminuria 2.9±2.5 mg/l; p=0.016), while interleukin-6 increased in parallel with the severity of the renal disease (1.9±1.5, 2.9±3.3, 3.6±3.1 ng/l; p<0.0001). In multiple regression analysis albumin excretion rate was the only variable independently associated with C-reactive protein (p=0.03), whereas albumin excretion rate (p=0.0003), HDL-cholesterol (p=0.0135) and duration of diabetes (p=0.0176) were independently associated with interleukin-6.

Conclusions/interpretation

Low-grade inflammatory markers are associated with diabetic nephropathy in Type 1 diabetic patients. The predictive value needs to be assessed.
Literatur
1.
Zurück zum Zitat Borch-Johnsen K, Andersen PK, Deckert T (1985) The effect of proteinuria on relative mortality in type 1 (insulin-dependent ) diabetes mellitus. Diabetologia 28:590–596PubMed Borch-Johnsen K, Andersen PK, Deckert T (1985) The effect of proteinuria on relative mortality in type 1 (insulin-dependent ) diabetes mellitus. Diabetologia 28:590–596PubMed
2.
Zurück zum Zitat Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM (2000) Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 58:1703–1710CrossRefPubMed Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM (2000) Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 58:1703–1710CrossRefPubMed
3.
Zurück zum Zitat Stehouwer CDA, Gall M-A, Twisk JWR, Knudsen E, Emeis JJ, Parving H-H (2002) Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Diabetes 51:1157–1165PubMed Stehouwer CDA, Gall M-A, Twisk JWR, Knudsen E, Emeis JJ, Parving H-H (2002) Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Diabetes 51:1157–1165PubMed
4.
Zurück zum Zitat Ridger PM (2001) High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103:1813–1818PubMed Ridger PM (2001) High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103:1813–1818PubMed
5.
Zurück zum Zitat Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131–2135PubMed Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131–2135PubMed
6.
Zurück zum Zitat Blake GJ, Ridker PM (2002) Tumour necrosis factor-alfa, inflammatory biomarkers, and atherogenesis. Eur Heart J 23:345–347CrossRefPubMed Blake GJ, Ridker PM (2002) Tumour necrosis factor-alfa, inflammatory biomarkers, and atherogenesis. Eur Heart J 23:345–347CrossRefPubMed
7.
Zurück zum Zitat Fried SK, Bunkin DA, Greenberg AS (1998) Omental and subcutaneous adipose tissue of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clinical Endocrinol Metab 83:847–850 Fried SK, Bunkin DA, Greenberg AS (1998) Omental and subcutaneous adipose tissue of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clinical Endocrinol Metab 83:847–850
8.
Zurück zum Zitat Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 82:4196–4200PubMed Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 82:4196–4200PubMed
9.
Zurück zum Zitat Akira S, Taga T, Kishimoto T (1993) Interleukin-6 in biology and medicine. Adv Immunol 54:1-78PubMed Akira S, Taga T, Kishimoto T (1993) Interleukin-6 in biology and medicine. Adv Immunol 54:1-78PubMed
10.
Zurück zum Zitat Shikano M, Sobajima H, Yoshikawa H et al. (2000) Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron 85:81–85PubMed Shikano M, Sobajima H, Yoshikawa H et al. (2000) Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron 85:81–85PubMed
11.
Zurück zum Zitat Pickup JC, Mattock MB, Chusney GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of the acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286–1292CrossRefPubMed Pickup JC, Mattock MB, Chusney GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of the acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286–1292CrossRefPubMed
12.
Zurück zum Zitat Orchard TJ, Chang Y, Ferrell RE, Petro N, Ellis DE (2002) Nephropathy in type 1 diabetes: A manifestation of insulin resistance and multiple genetic susceptibilities? Kidney Int 62:963–970CrossRefPubMed Orchard TJ, Chang Y, Ferrell RE, Petro N, Ellis DE (2002) Nephropathy in type 1 diabetes: A manifestation of insulin resistance and multiple genetic susceptibilities? Kidney Int 62:963–970CrossRefPubMed
13.
Zurück zum Zitat Myrup B, deMaat M, Rossing P, Gram J, Kluft C, Jespersen J (1996) Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Thromb Res 81:485–490CrossRefPubMed Myrup B, deMaat M, Rossing P, Gram J, Kluft C, Jespersen J (1996) Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Thromb Res 81:485–490CrossRefPubMed
14.
Zurück zum Zitat Schalwijk CG, Poland DCW, van Dijk W et al. (1999) Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351–357CrossRefPubMed Schalwijk CG, Poland DCW, van Dijk W et al. (1999) Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351–357CrossRefPubMed
15.
Zurück zum Zitat Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ (2000) Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49:626–632 Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ (2000) Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49:626–632
16.
Zurück zum Zitat Levey A, Bosch J, Luan P, Lewis J, Green T, RogersN, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Int Med 130:461–470 Levey A, Bosch J, Luan P, Lewis J, Green T, RogersN, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Int Med 130:461–470
17.
Zurück zum Zitat National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board (2002). K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39 [Suppl 2]:1–246 National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board (2002). K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39 [Suppl 2]:1–246
18.
Zurück zum Zitat Cockroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMed Cockroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMed
19.
Zurück zum Zitat Teppo AM, Törnroth T, Honkanen E, Grönhagen-Riska C (2003) Elevated serum C-reactive protein associates with deterioration of renal function in transplant recipients. Clin Nephrol (in press) Teppo AM, Törnroth T, Honkanen E, Grönhagen-Riska C (2003) Elevated serum C-reactive protein associates with deterioration of renal function in transplant recipients. Clin Nephrol (in press)
20.
Zurück zum Zitat Stenvinkel P, Andersson P, Wang T et al. (1999) Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure? J Intern Med 246:503–507CrossRefPubMed Stenvinkel P, Andersson P, Wang T et al. (1999) Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure? J Intern Med 246:503–507CrossRefPubMed
21.
Zurück zum Zitat Guijarro C, Egido J (2001) Transcription factor-κB (NF-κB) and renal disease. Kidney Int 59:415–424CrossRefPubMed Guijarro C, Egido J (2001) Transcription factor-κB (NF-κB) and renal disease. Kidney Int 59:415–424CrossRefPubMed
22.
Zurück zum Zitat Pedersen BK, Steensberg A, Scherling P (2001) Muscle-derived interleukin-6: possible biological effects. J Physiol 536:329–327PubMed Pedersen BK, Steensberg A, Scherling P (2001) Muscle-derived interleukin-6: possible biological effects. J Physiol 536:329–327PubMed
23.
Zurück zum Zitat Schwendler S, Schintzel R, Vaith P, Wanner C (2001) Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int Suppl 78:S32–36PubMed Schwendler S, Schintzel R, Vaith P, Wanner C (2001) Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int Suppl 78:S32–36PubMed
24.
Zurück zum Zitat Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–3398PubMed Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–3398PubMed
Metadaten
Titel
Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients
verfasst von
M. Saraheimo
A.-M. Teppo
C. Forsblom
J. Fagerudd
P.-H. Groop, MD
on behalf of the FinnDiane Study Group
Publikationsdatum
01.10.2003
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 10/2003
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1194-5

Weitere Artikel der Ausgabe 10/2003

Diabetologia 10/2003 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.